IZOTROPIC CORP. (1R3) - Net Assets
Based on the latest financial reports, IZOTROPIC CORP. (1R3) has net assets worth €-5.34 Million EUR (≈ $-6.25 Million USD) as of January 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€685.34K ≈ $801.23K USD) and total liabilities (€6.03 Million ≈ $7.05 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read 1R3 total debt and obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-5.34 Million |
| % of Total Assets | -779.65% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
IZOTROPIC CORP. - Net Assets Trend (2022–2025)
This chart illustrates how IZOTROPIC CORP.'s net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of IZOTROPIC CORP. for the complete picture of this company's asset base.
Annual Net Assets for IZOTROPIC CORP. (2022–2025)
The table below shows the annual net assets of IZOTROPIC CORP. from 2022 to 2025. For live valuation and market cap data, see IZOTROPIC CORP. (1R3) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-04-30 | €-4.86 Million ≈ $-5.68 Million |
-26.33% |
| 2024-04-30 | €-3.85 Million ≈ $-4.50 Million |
-25.13% |
| 2023-04-30 | €-3.07 Million ≈ $-3.59 Million |
-720.57% |
| 2022-04-30 | €-374.59K ≈ $-437.93K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to IZOTROPIC CORP.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 815692700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €17.28 Million | % |
| Total Equity | €-4.86 Million | 100.00% |
IZOTROPIC CORP. Competitors by Market Cap
The table below lists competitors of IZOTROPIC CORP. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Medadvisor Ltd
AU:MDR
|
$9.91 Million |
|
Check-Cap Ltd
F:7CC
|
$9.91 Million |
|
Euroland Corporate SA
PA:MLERO
|
$9.92 Million |
|
Together Startup Network Ltd
TA:TGTR
|
$9.92 Million |
|
Agro Yasa Lestari PT Tbk
JK:AYLS
|
$9.90 Million |
|
HYDROTOR SA
WAR:HDR
|
$9.90 Million |
|
Meta Epsi Tbk PT
JK:MTPS
|
$9.90 Million |
|
Wahana Pronatural
JK:WAPO
|
$9.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IZOTROPIC CORP.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -3,846,254 to -4,858,987, a change of -1,012,733.
- Net loss of 3,139,710 reduced equity.
- New share issuances of 920,000 increased equity.
- Other factors increased equity by 1,206,977.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.14 Million | -64.62% |
| Share Issuances | €920.00K | +18.93% |
| Other Changes | €1.21 Million | +24.84% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares IZOTROPIC CORP.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-04-30 | €-0.01 | €0.18 | x |
| 2023-04-30 | €-0.06 | €0.18 | x |
| 2024-04-30 | €-0.07 | €0.18 | x |
| 2025-04-30 | €-0.08 | €0.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IZOTROPIC CORP. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-6.62 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-5.35 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | €-1.18 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | €-2.65 Million |
Industry Comparison
This section compares IZOTROPIC CORP.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $4,071,423,437
- Average return on equity (ROE) among peers: -209.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IZOTROPIC CORP. (1R3) | €-5.34 Million | 0.00% | N/A | $9.91 Million |
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | $637.00K | -555.57% | 21.06x | $1.47 Million |
| Check-Cap Ltd (7CC) | $6.23 Million | -221.94% | 0.51x | $9.91 Million |
| GENINCODE PLC LS -01 (9PL) | $1.29 Million | -544.30% | 2.25x | $8.48 Million |
| INOVIQ LTD. (EGQ0) | $19.62 Million | -45.73% | 0.10x | $29.30 Million |
| Eurofins Scientific SE (ESF0) | $5.14 Billion | 6.04% | 1.12x | $11.18 Billion |
| ICON Public Limited Company (IJF) | $9.24 Billion | 6.63% | 0.84x | $8.69 Billion |
| NanoRepro AG (NN6) | $238.29K | -330.81% | 0.82x | $18.79 Million |
| WuXi AppTec Co. Ltd (WX8) | $18.17 Billion | 12.44% | 0.25x | $8.77 Billion |
About IZOTROPIC CORP.
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. The company develops and commercializes IzoView, a CT diagnostic imaging device with a platform of targeted uses offering high resolution, true 3D dedicated breast imaging with 360-degree image acquisition and can be used with or without injectable contrast. Izotropic Corporation … Read more